Please ensure Javascript is enabled for purposes of website accessibility

3 Things You Need to Know About Kite Pharma's First Quarter

By Todd Campbell - May 10, 2016 at 4:01PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Q1 results offer important insight into the company's plans for KTE-C19, its pipeline, and its financials.

Image source: Kite Pharma.

After reporting its first-quarter financials, investors might be wondering if Kite Pharma's (NASDAQ: KITE) shares should be bought or sold. Here are three key takeaways investors should consider before pressing the buy or sell buttons.

No. 1: First-mover advantage
Kite Pharma's management expects to report data from a pivotal phase 2 trial evaluating its CAR-T therapy KTE-C19 in aggressive non-Hodgkin lymphoma (NHL) patients later this year. KTE-C19 is a therapy that reengineers a patient's immune system to find and destroy cancer cells expressing the C19 antigen, and if results are positive, then Kite Pharma plans to file for FDA approval before the end of the year.

Delivering on that aggressive timeline could position Kite Phama as the first CAR-T therapy on the market, and that could pave the way for the company reporting substantial revenue by the end of next year.

Previously, Kite Pharma reported that 22 of 41 patients with aggressive NHL treated with KTE-C19 achieved complete responses, and that durable complete responses are stretching out as long as three years. Also, Kite Pharma reported recently that one of seven patients with chemorefractory NHL remained a complete responder nine months after KTE-C19, and that two other patients in this subgroup were still complete responders after six months. These findings are remarkable given that historically, median overall survival in tough-to-treat NHL patients is about 3.6 months.

Because patients with chemorefractory NHL have a poor prognosis and few treatment options, Kite Pharma is already laying the groundwork for potential KTE-C19 commercialization. Last quarter, management made advances in prepping for commercial-scale production of KTE-C19 that it estimates will allow it to produce between 4,000 to 5,000 personalized patient therapies annually. The company's c-suite is also planning market and payer strategies now so it can hit the ground running if the FDA gives it the go-ahead next year.

No. 2: Pipeline expansion
In addition to advancing KTE-C19 in advanced NHL, the company is also making progress in expanding the number of studies it has under way so its therapies can address more patients.

For example, a collaboration with Roche that will combine Roche's atezolizumab, a checkpoint inhibitor, with KTE-C19 is expected to begin recruiting patients later this year. 

Also, the company plans to study KTE-C19 in follicular lymphoma, chronic lymphocytic leukemia, and in earlier stages of diffuse large B cell lymphoma. And, the company is making progress on T-cell receptor (TCR) therapies that may someday offer hope to patients diagnosed with solid tumors. The company hopes to file an IND with the FDA later this year so it can begin human clinical studies of MAGE A3 soon.

Image source: Amgen.

Finally, Kite Pharma and Amgen (AMGN 0.62%) agreed in January 2015 to combine Kite Pharma's extensive CAR-T knowledge with Amgen's extensive array of cancer targets to develop next-generation CAR-T therapies. That collaboration is progressing ahead of schedule, and that's got Kite Pharma thinking it'll be able to file the first IND from this collaboration in 2017.

No. 3: Financial firepower
Developing therapies that reengineer a patient's T-cells to better target cancer cells is incredibly complex and expensive. Fortunately, Kite Pharma's financial footing appears stable.

Last quarter, the company spent $34.4 million on research and development and $16.5 million on general and administrative expenses. Overall, that spending translated into a cash burn rate of $37.3 million in the quarter, and based on the pace of spending, management is guiding for total cash burn of at least $235 million this year.

That's a lot of money, but Kite Pharma exited March with $575 million in cash and investments on its books and no debt, and that cushion prompted Kite Pharma's CFO, Cynthia Butitta, to say on the earnings conference call that "current cash and investments are sufficient to fund our operations through commercial launch of KTE-C19."

Obviously, that statement depends on getting a green light from the FDA next year, but assuming that happens without a hitch, it appears unlikely that there are any dilutive stock or debt offerings on the horizon.

Tying it together
More than 90% of cancer drugs fail in clinical trials, and many of those failures occur in late-stage trials when medicines get tested in larger patient populations. Given that failure rate, there's no certainty KTE-C19's current studies will confirm those from prior studies. Another risk is that the FDA will balk at approving KTE-C19 without it conducting a larger study. The FDA has to weigh efficacy against safety, and since life-threatening cytokine responses have been observed with CAR-T therapies, there could be reason for regulators to press pause.

Nevertheless, Kite Pharma is at the forefront of CAR-T development, and the potential for it to win first-mover advantage in a patient population that has a big unmet need might make this a stock worth owning. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amgen Inc. Stock Quote
Amgen Inc.
AMGN
$249.04 (0.62%) $1.54
Roche Holding AG Stock Quote
Roche Holding AG
RHHBY
$41.86 (1.82%) $0.75

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.